SGLT2 inhibitor use and disparities in all-cause mortality in type 2 diabetes: insights from a multi-ethnic population
Diabetologia · 2026-08 · 69 (8) · 2189-2199
DOI: 10.1007/s00125-026-06733-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetologia, online erschienen am 27.04.2026. Verfasst von Lynne Chepulis und 13 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research Centre, University of Waikato, Hamilton, New Zealand. Lynnec@waikato.ac.nz. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Maori People, Sodium-Glucose Transporter 2 Inhibitors, White People. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Research Council of New Zealand, University of Waikato.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims/hypothesis Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are known to reduce cardiovascular and all-cause mortality in people with type 2 diabetes, but there are limited data regarding mortality outcomes in different ethnic groups (including Indigenous peoples). This study reports on mortality outcomes in a population in Aotearoa New Zealand (hereafter New Zealand) with type 2 diabetes, following the funded availability of the SGLT2i empagliflozin with prioritised access for Māori and Pacific people.
Methods
Data were collected from primary care records for those aged 18–75 years with type 2 diabetes (Auckland/Waikato regions of New Zealand; February 2021 to December 2023; n =59,505). These data were linked to national medication-dispensing and mortality records for 2021–2024 via national health identifier numbers. Following propensity matching and Cox modelling for ethnicity, age, gender, medication use, baseline HbA 1c and cardiovascular and/or renal disease/risk (CVRD) status (yes/no), mortality rates were compared by ethnicity in those with and without CVRD and who did/did not initiate empagliflozin. This study was reported in accordance with the CONSIDER statement, used to strengthen the reporting of research involving Indigenous peoples. The study was funded by the Health Research Council of New Zealand.
Results
Following matching, two groups of 12,792 individuals were identified. Annualised crude mortality (deaths per 1000 individuals per year) was higher in those not dispensed with SGLT2i than in those receiving SGLT2i (35.2 vs 13.1 in those with CVRD and 7.7 vs 3.6 in those without CVRD, respectively). After adjustment, the greatest difference in mortality with SGLT2i use was seen in Māori (HR 0.475; 95% CI 0.336, 0.672; p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Research Centre, University of Waikato, Hamilton, New Zealand. Lynnec@waikato.ac.nz.
- School of Computing and Mathematical Sciences, University of Waikato, Hamilton, New Zealand.
- School of Medicine, Western Sydney University, Sydney, NSW, Australia.
- Medical Research Centre, University of Waikato, Hamilton, New Zealand.
- Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
- Health New Zealand / Te Whatu Ora Te Toka Tumai, Auckland, New Zealand.
Förderung
- Health Research Council of New Zealand
- University of Waikato
Zitieren
APA
Chepulis, L., Gan, H., Simmons, D., Rodrigues, M., Keenan, R., Murphy, R., Kenealy, T., Te Karu, L., Magliano, D., Scott-Jones, J., Moffitt, A., Lao, C., Lawrenson, R., & Paul, R. G. (2026). SGLT2 inhibitor use and disparities in all-cause mortality in type 2 diabetes: insights from a multi-ethnic population. Diabetologia, 69(8), 2189-2199. https://doi.org/10.1007/s00125-026-06733-2
Vancouver
Chepulis L, Gan H, Simmons D, Rodrigues M, Keenan R, Murphy R, et al. SGLT2 inhibitor use and disparities in all-cause mortality in type 2 diabetes: insights from a multi-ethnic population. Diabetologia. 2026;69(8):2189-2199. doi:10.1007/s00125-026-06733-2
BibTeX
@article{Chepulis2026,
author = {Chepulis, Lynne and Gan, Han and Simmons, David and Rodrigues, Mark and Keenan, Rawiri and Murphy, Rinki and Kenealy, Tim and Te Karu, Leanne and Magliano, Dianna and Scott-Jones, Jo and Moffitt, Allan and Lao, Chunhuan and Lawrenson, Ross and Paul, Ryan G},
title = {SGLT2 inhibitor use and disparities in all-cause mortality in type 2 diabetes: insights from a multi-ethnic population},
journal = {Diabetologia},
year = {2026},
volume = {69},
number = {8},
pages = {2189--2199},
doi = {10.1007/s00125-026-06733-2}
}
EUVIMED